Cryosite Limited (AU:CTE)
ASX:CTE
Want to see AU:CTE full AI Analyst Report?
CTE Stock Chart & Stats
AU$1.00
-AU$0.05(-6.02%)
At close: 4:00 PM EST
AU$1.00
-AU$0.05(-6.02%)
Day’s Range― - ―
52-Week RangeAU$0.60 - AU$1.30
Previous CloseN/A
Volume1.46K
Average Volume (3M)1.97K
Market Cap
AU$51.74M
Enterprise ValueAU$58.02M
Total Cash (Recent Filing)AU$2.54M
Total Debt (Recent Filing)AU$8.82M
Price to Earnings (P/E)23.7
Beta-0.13
Next Earnings
Aug 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.04
Shares Outstanding48,809,563
10 Day Avg. Volume3,337
30 Day Avg. Volume1,969
Financial Highlights & Ratios
PEG Ratio8.08
Price to Book (P/B)15.22
Price to Sales (P/S)2.58
P/FCF Ratio24.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High MarginsSustained high gross (62.98%) and healthy net margins (13.35%) indicate strong pricing power and cost control in core operations. These margins support durable profitability, funding for R&D and reinvestment, and provide a buffer against industry cost pressures over the medium term.
Consistent Revenue GrowthRecurring top-line growth of ~9.85% demonstrates continued market demand and successful commercial execution. This pace supports capacity utilization and gradual scaling, enabling predictable revenue base that underpins medium-term investment and margin sustainability.
Strong Return On EquityVery high ROE (78.86%) reflects efficient use of shareholder capital and strong profit generation from existing equity. Combined with a manageable debt-to-equity (~0.95), this suggests the business converts capital into returns effectively, a durable advantage if cash generation holds.
Bears Say
Declining Free Cash FlowA 32.88% decline in free cash flow growth is a material structural weakness: it reduces capacity to fund capex, repay debt, or return capital. Sustained FCF deterioration can force higher leverage or equity raises, weakening financial flexibility over the medium term.
Earnings Cash ConversionOCF failing to fully cover net income signals earnings quality concerns and cash conversion lag. If persistent, this erodes the sustainability of reported profits and limits internally generated funds for growth or debt servicing, raising medium-term operational risk.
Reliance On Debt / Low Equity RatioA D/E near 0.95 and low equity ratio indicate reliance on debt financing. In conjunction with weaker cash conversion, this elevates refinancing and solvency risk during downturns, reducing strategic flexibility and potentially increasing funding costs over the medium term.
Cryosite Limited News
CTE FAQ
What was Cryosite Limited’s price range in the past 12 months?
Cryosite Limited lowest share price was AU$0.60 and its highest was AU$1.30 in the past 12 months.
What is Cryosite Limited’s market cap?
Cryosite Limited’s market cap is AU$51.74M.
When is Cryosite Limited’s upcoming earnings report date?
Cryosite Limited’s upcoming earnings report date is Aug 21, 2026 which is in 61 days.
How were Cryosite Limited’s earnings last quarter?
Cryosite Limited released its earnings results on Feb 26, 2026. The company reported AU$0.023 earnings per share for the quarter, beating the consensus estimate of N/A by AU$0.023.
Is Cryosite Limited overvalued?
According to Wall Street analysts Cryosite Limited’s price is currently Overvalued.
Does Cryosite Limited pay dividends?
Cryosite Limited pays a Annually dividend of AU$0.02 which represents an annual dividend yield of N/A. See more information on Cryosite Limited dividends here
What is Cryosite Limited’s EPS estimate?
Cryosite Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cryosite Limited have?
Cryosite Limited has 48,809,563 shares outstanding.
What happened to Cryosite Limited’s price movement after its last earnings report?
Cryosite Limited reported an EPS of AU$0.023 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Cryosite Limited?
Currently, no hedge funds are holding shares in AU:CTE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cryosite Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
15.34%
12-Months-Change
Fundamentals
Return on Equity
72.82%
Trailing 12-Months
Asset Growth
39.09%
Trailing 12-Months
Company Description
Cryosite Limited
Cryosite Limited, founded in 1999 and headquartered in South Granville, Australia, specializes in providing outsourced logistics and storage solutions to the life sciences industry within Australia. The company operates through two distinct divisions. Its Clinical Trials and Biological Services Logistics segment offers comprehensive support to the clinical research and pharmaceutical sectors, encompassing services such as specialized temperature-controlled and general biological storage, precise labeling, secondary packaging, and end-to-end supply chain management capabilities like scheduled drug distribution, returns processing, material destruction, status oversight, comparator sourcing, and validated import/export and transportation. The second division, Cord Blood and Tissues Storage, focuses on the long-term cryogenic preservation of cord blood and tissue samples. Cryosite's client base spans the research, medical, pharmaceutical, veterinary, and biotechnology industries.
Technical Analysis
BCAL Diagnostics Limited
―
Rhythm Biosciences Ltd.
―
Lumos Diagnostics Holdings Ltd.
―
Inoviq Ltd
―
Microba Life Sciences Limited
―
Options Prices
Currently, No data available
---